Benefits
Pediatric AAD prevention RCT (Zhou 2023 PMC10076687)
Zhou Q, Dai W, Bao Y et al. 2023 (Clin Transl Med, doi:10.1002/ctm2.1184) — first multi-center DOUBLE-BLIND RCT (ChiCTR-IPR-16009033) of B. licheniformis CMCC63516 (Zhengchangsheng, NorthEast Pharm) in Chinese pediatric AAD. Found BASELINE GUT MICROBIOME structure impacts probiotic protection — important biomarker stratification finding. Limitations acknowledged: small sample size + non-uniform antibiotics. First published double-blind RCT for AAD prevention in Chinese children.
CDI gut microbiota preservation 5-day adjunct (PMC11858508)
5-day B. licheniformis treatment alongside vancomycin in C. difficile infection patients — preserved gut microbiota during classical CDI antibiotic treatment. Mechanism: spore-based probiotic survives stomach acid + germinates in intestines + supports microbiota recovery during dysbiosis. Important CDI-adjunct evidence.
Sporulation pharmaceutical advantage
B. licheniformis spores withstand chemical/physical challenges (air drying, high temperatures, high pressure, UV light, acidity) — pharmaceutical advantage allowing greater survival in stomach + arrival to small intestine without enteric coating. Foundation pharmaceutical benefit shared with other Bacillus probiotics.
Microbiota modulation (systematic review PMC9549136)
Systematic review (PMC9549136, 2022) of 68 articles documenting B. licheniformis applications. Most addressed area: GASTROINTESTINAL system — microbiota modulation, gut benefits, treatment of enteritis/colitis/diarrhea. Foundational systematic-review evidence base.
Bacitracin antibiotic production
B. licheniformis produces BACITRACIN — natural antibiotic active against gram-positive bacteria. Mechanism: direct antimicrobial activity contributing to competitive exclusion of pathogenic bacteria. Distinguishing pharmacology among Bacillus probiotics.
Component of MegaSporeBiotic (SL-307)
B. licheniformis SL-307 is one of 5 strains in MEGASPOREBIOTIC™ formulation — contributing bacitracin antimicrobial activity to multi-strain spore probiotic. Royal Holloway University origin (Simon Cutting). Standalone B. licheniformis evidence supports both standalone use + multi-strain formulation contribution.
Spore germination + colonization
Spores germinate in lower GI tract → vegetative cells produce metabolites + antimicrobials. Distinguishing from Lactobacillus/Bifidobacterium probiotics which require viable delivery. Practical pharmaceutical advantage for room-temperature storage + delivery efficiency.
Mechanism of action
Spore-form delivery (heat/acid/bile resistance)
Spores withstand chemical/physical challenges + survive gastric acidity. Mechanism: efficient delivery to lower GI without enteric coating. Distinguishing pharmaceutical advantage shared with Bacillus species.
Bacitracin antibiotic production
Produces BACITRACIN — natural antibiotic against gram-positive pathogens. Mechanism: direct antimicrobial activity + competitive exclusion. Distinguishing among Bacillus species.
Microbiota modulation during dysbiosis
Modulates gut microbiota during antibiotic-induced dysbiosis. Mechanism: competitive exclusion + commensal flora support. Foundation for AAD prevention + CDI-adjunct applications.
Spore germination + vegetative metabolite production
Spores germinate in lower GI → vegetative cells produce SCFAs + antimicrobials. Mechanism: delayed-action live activity vs immediate Lactobacillus/Bifidobacterium effects.
Anti-inflammatory effects
Modulates gut inflammatory response — supports mucosal immune regulation. Mechanism: contributes to symptomatic relief in dysbiosis-related conditions.
Baseline microbiome interaction
Zhou 2023 finding: BASELINE gut microbiome structure impacts probiotic protective effect. Mechanism: pre-existing microbiome diversity affects response variability — important for clinical translation + biomarker stratification.
Clinical trials
Multi-center double-blind RCT (Zhou Q, Dai W, Bao Y et al. 2023, Clin Transl Med, doi:10.1002/ctm2.1184, PMC10076687, ChiCTR-IPR-16009033). Multi-hospital Chinese sites including Shenzhen Children's Hospital + Shenyang Children's Hospital + Tianjin Medical University + Shenjing Hospital.
Chinese pediatric patients on antibiotics. B. licheniformis CMCC63516 (Zhengchangsheng, NorthEast Pharm) vs placebo. Baseline gut microbiome assessed via 16S rRNA.
First published double-blind RCT for AAD prevention in Chinese children. BASELINE gut microbiome structure impacts probiotic protection — important biomarker stratification finding. P. copri + B. coprocola + B. plebeius positive correlations. Limitations: small sample size + non-uniform antibiotics. Funded by Shenzhen Key Medical Discipline + Peking University Shenzhen Hospital. NorthEast Pharm provided B. licheniformis Zhengchangsheng.
Clinical trial of B. licheniformis adjunct to vancomycin (PMC11858508).
C. difficile infection patients. 5-day B. licheniformis treatment alongside classical vancomycin treatment.
Preserved gut microbiota during CDI antibiotic treatment. Mechanism: spore-based probiotic survives stomach acid + germinates in intestines + supports microbiota recovery during dysbiosis. Important CDI-adjunct evidence supporting probiotic use during antibiotic therapy.
Systematic review (PMC9549136, Front Microbiol 2022). PRISMA guidelines. Period 2016-mid-2022.
68 articles covering human + cellular + animal models. PubMed search 'Bacillus licheniformis' + 'B. licheniformis probiotic'.
Systematic review documenting B. licheniformis applications. Most addressed area: GASTROINTESTINAL system — microbiota modulation, gut benefits, treatment of enteritis/colitis/diarrhea. Sporulation advantage for stomach acid survival + small intestine arrival. Foundational systematic-review evidence base.
About this ingredient
BACILLUS LICHENIFORMIS is a SPORE-FORMING Bacillus probiotic with BACITRACIN ANTIBIOTIC PRODUCTION.
KEY STRAINS: CMCC63516 (Zhengchangsheng, NorthEast Pharm — Chinese clinical use); SL-307 (MegaSporeBiotic component, Royal Holloway University origin per Simon Cutting). Standalone use distinct from MegaSporeBiotic SL-307 multi-strain context. Spore-form heat/acid/bile resistant — survives stomach acid + arrives small intestine without enteric coating. PIVOTAL CLINICAL EVIDENCE: ZHOU Q, DAI W, BAO Y et al. 2023 PMC10076687 (Clin Transl Med, doi:10.1002/ctm2.1184, ChiCTR-IPR-16009033) — first multi-center DOUBLE-BLIND RCT of B. licheniformis CMCC63516 in Chinese pediatric AAD. Multi-hospital Chinese sites including Shenzhen Children's Hospital + Shenyang Children's Hospital + Tianjin Medical University + Shenjing Hospital. RESULTS: BASELINE GUT MICROBIOME structure impacts probiotic protection — important biomarker stratification finding. P. copri + B. coprocola + B. plebeius positive correlations. Limitations: small sample size + non-uniform antibiotics. PMC11858508 — 5-day B. licheniformis treatment alongside vancomycin in CDI patients PRESERVED gut microbiota during classical CDI antibiotic treatment. PMC9549136 (Front Microbiol 2022) systematic review of 68 articles — most addressed area: GASTROINTESTINAL system (microbiota modulation, gut benefits, treatment of enteritis/colitis/diarrhea).
MECHANISMS: SPORE-FORM DELIVERY (heat/acid/bile resistance — survives gastric transit, no enteric coating); BACITRACIN ANTIBIOTIC production (gram-positive antimicrobial — distinguishing among Bacillus species); MICROBIOTA MODULATION during dysbiosis (competitive exclusion + commensal support); SPORE GERMINATION + vegetative metabolite production; anti-inflammatory effects; BASELINE MICROBIOME INTERACTION (Zhou 2023 finding — pre-existing microbiome impacts response variability). EVIDENCE: 3/5 reflects: (1) ZHOU 2023 PIVOTAL multi-center double-blind RCT for Chinese pediatric AAD, (2) PMC11858508 CDI gut microbiota preservation 5-day adjunct evidence, (3) PMC9549136 SYSTEMATIC REVIEW of 68 articles, (4) WELL-CHARACTERIZED spore + bacitracin + microbiota mechanisms, (5) STANDALONE STRAIN evidence distinct from MegaSporeBiotic context, (6) MEGASPOREBIOTIC SL-307 component (multi-strain formulation contribution), (7) industry-related context (NorthEast Pharm Zhengchangsheng, Microbiome Labs SL-307), (8) HONEST LIMITATIONS — small sample sizes + non-uniform antibiotics in Zhou 2023; geographic concentration in Chinese pediatric population, (9) BASELINE MICROBIOME stratification finding important for clinical translation, (10) higher-evidence than typical 'spore probiotic' for AAD prevention due to multi-center double-blind RCT methodology. SAFETY: Excellent — extensive Chinese clinical use record + spore-based safety profile. Best positioned as: (a) PEDIATRIC AAD PREVENTION (Zhou 2023 evidence), (b) CDI ADJUNCT alongside vancomycin (PMC11858508 evidence), (c) ANTIBIOTIC-COMPATIBLE probiotic (spore-form survives antibiotic exposure), (d) GASTROINTESTINAL HEALTH adjunct (systematic review evidence base), (e) MULTI-STRAIN FORMULATION component (MegaSporeBiotic SL-307 context), (f) ROOM-TEMPERATURE STABLE — practical advantage, (g) PREGNANCY: limited specific data, (h) IMMUNOCOMPROMISED: caution, (i) BACITRACIN ALLERGIES: theoretical caution, (j) higher-evidence than typical standalone Bacillus probiotic for AAD prevention due to dedicated multi-center RCT methodology. Honest framing: B. licheniformis has solid emerging evidence as standalone probiotic — Zhou 2023 first multi-center double-blind RCT for Chinese pediatric AAD documented BASELINE MICROBIOME impacts probiotic protection (important biomarker stratification finding). PMC11858508 CDI gut microbiota preservation extends application to severe AAD context. Spore-form pharmaceutical advantage allows antibiotic-compatible dosing. SL-307 component evidence (MegaSporeBiotic) supports multi-strain formulation application. NorthEast Pharm Zhengchangsheng (China) industry context warrants caveat but multi-hospital methodology rigorous. Reasonable AAD prevention + CDI adjunct application based on emerging evidence — particularly compelling for pediatric antibiotic-treated patients seeking spore-based probiotic with bacitracin antimicrobial activity.